These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 20041820)

  • 1. PUFA for human health: diet or supplementation?
    Abete P; Testa G; Galizia G; Della-Morte D; Cacciatore F; Rengo F
    Curr Pharm Des; 2009; 15(36):4186-90. PubMed ID: 20041820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differentiating prescription omega-3-acid ethyl esters (P-OM3) from dietary-supplement omega-3 fatty acids.
    Brunton S; Collins N
    Curr Med Res Opin; 2007 May; 23(5):1139-45. PubMed ID: 17519081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Omega-3 Fatty Acid Formulations in Cardiovascular Disease: Dietary Supplements are Not Substitutes for Prescription Products.
    Fialkow J
    Am J Cardiovasc Drugs; 2016 Aug; 16(4):229-239. PubMed ID: 27138439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omega-3 fatty acid exposure with a low-fat diet in patients with past hypertriglyceridemia-induced acute pancreatitis; an exploratory, randomized, open-label crossover study.
    Dunbar RL; Gaudet D; Davidson M; Rensfeldt M; Yang H; Nilsson C; Kvarnström M; Oscarsson J
    Lipids Health Dis; 2020 May; 19(1):117. PubMed ID: 32473640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prescription Omega-3 Fatty Acid Products and Dietary Supplements Are Not Interchangeable.
    Hilleman D; Smer A
    Manag Care; 2016 Jan; 25(1):46-52. PubMed ID: 26882630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long chain omega-3 dietary supplements: a review of the National Library of Medicine Herbal Supplement Database.
    Zargar A; Ito MK
    Metab Syndr Relat Disord; 2011 Aug; 9(4):255-71. PubMed ID: 21787228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Single-dose, Comparative Bioavailability Study of a Formulation containing OM3 as Phospholipid and Free Fatty Acid to an Ethyl Ester Formulation in the Fasting and Fed States.
    Lapointe JF; Harvey L; Aziz S; Jordan H; Hegele RA; Lemieux P
    Clin Ther; 2019 Mar; 41(3):426-444. PubMed ID: 30799231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic Bioavailability and Dose Proportionality of Omega-3 Administered in Free Fatty Acid Form Compared With Ethyl Ester Form: Results of a Phase 1 Study in Healthy Volunteers.
    Offman E; Davidson M; Abu-Rashid M; Chai P; Nilsson C
    Eur J Drug Metab Pharmacokinet; 2017 Oct; 42(5):815-825. PubMed ID: 28116646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies to improve bioavailability of omega-3 fatty acids from ethyl ester concentrates.
    Maki KC; Dicklin MR
    Curr Opin Clin Nutr Metab Care; 2019 Mar; 22(2):116-123. PubMed ID: 30550388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on marine omega-3 fatty acids: management of dyslipidemia and current omega-3 treatment options.
    Weintraub H
    Atherosclerosis; 2013 Oct; 230(2):381-9. PubMed ID: 24075771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fortification of foods with omega-3 polyunsaturated fatty acids.
    Ganesan B; Brothersen C; McMahon DJ
    Crit Rev Food Sci Nutr; 2014; 54(1):98-114. PubMed ID: 24188235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omega-3 fatty acids and cardiovascular disease: new developments and applications.
    Harris WS; Dayspring TD; Moran TJ
    Postgrad Med; 2013 Nov; 125(6):100-13. PubMed ID: 24200766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk stratification by the "EPA+DHA level" and the "EPA/AA ratio" focus on anti-inflammatory and antiarrhythmogenic effects of long-chain omega-3 fatty acids.
    Rupp H; Wagner D; Rupp T; Schulte LM; Maisch B
    Herz; 2004 Nov; 29(7):673-85. PubMed ID: 15580322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omega-3 fatty acids in the gravid pig uterus as affected by maternal supplementation with omega-3 fatty acids.
    Brazle AE; Johnson BJ; Webel SK; Rathbun TJ; Davis DL
    J Anim Sci; 2009 Mar; 87(3):994-1002. PubMed ID: 18997072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of supplemental long-chain omega-3 fatty acids and risk for cardiac death: An updated meta-analysis and review of research gaps.
    Maki KC; Palacios OM; Bell M; Toth PP
    J Clin Lipidol; 2017; 11(5):1152-1160.e2. PubMed ID: 28818347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do we need 'new' omega-3 polyunsaturated fatty acids formulations?
    Cicero AF; Morbini M; Borghi C
    Expert Opin Pharmacother; 2015 Feb; 16(3):285-8. PubMed ID: 25474717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel, multi-ingredient supplement to manage elevated blood lipids in patients with no evidence of cardiovascular disease: a pilot study.
    Hobbs T; Caso R; McMahon D; Nymark M
    Altern Ther Health Med; 2014; 20(5):18-23. PubMed ID: 25141367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia.
    McKenney JM; Sica D
    Pharmacotherapy; 2007 May; 27(5):715-28. PubMed ID: 17461707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omega 3 and omega 6 fatty acids intake and dietary sources in a representative sample of Spanish adults.
    González-Rodríguez LG; Aparicio A; López-Sobaler AM; Ortega RM
    Int J Vitam Nutr Res; 2013; 83(1):36-47. PubMed ID: 24220163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: A Narrative Review.
    Hilleman DE; Wiggins BS; Bottorff MB
    Adv Ther; 2020 Feb; 37(2):656-670. PubMed ID: 31919792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.